An observational study in Pyelonephritis Acute and Kidney Transplantation Recipients, sponsored by Central Hospital, Nancy, France. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-27.
Sponsored by Central Hospital, Nancy, France · Observational
The aim of this study is to evaluate the impact of the duration of antibiotic therapy on the risk of recurrence in kidney graft pyelonephritis. The secondary objectives are to identify the factors associated with the duration of antibiotic therapy in acute kidney graft pyelonephritis, identify the factors associated with recurrence of acute kidney graft pyelonephritis within 3 months, evaluate the impact of the duration of antibiotic therapy on antibiotic-related complications and assess the impact of the duration of antibiotic therapy on the progression of renal function after acute kidney graft pyelonephritis.
Central Hospital, Nancy, France is the lead sponsor of 798 studies on the registry; 186 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Every patient with AGPN during the study period
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Relaspe AGPN
Rehospitalization for acute kidney graft pyelonephritis (AGPN) within three months after completion of treatment
Time frame: 3 month
Early AGPN relapse
Rehospitalization for acute kidney graft pyelonephritis (AGPN) within one month after completion of treatment
Time frame: 1 month
ITU relapse
Antibiotic treatment for urinary tract infection within 3 months after completion of treatment.
Time frame: 3 month
Identical microorganism relapsing AGPN
New episode of AGPN with the same pathogen within 3 months after completion of treatment
Time frame: 3 month
Multidrug resistant emerging pathogens
Infection with a multidrug-resistant bacteria within 3 months after completion of treatment
Time frame: 3 month
Clostridioides difficile colitis
Occurrence of Clostridioides difficile colitis within 3 months after completion of treatment
Time frame: 3 month
Early kidney function evolution
Evolution of renal function (creatininemia) 1 month after completion of treatment for APNAG.
Time frame: 1 month
3 month kidney function evolution
Evolution of renal function (creatininemia) 3 +/- 21 days after completion of treatment for AGPN
Time frame: 3 month and 21 days
Risk factors
Clinical and biological Factors associated with AGPN recurrence independently of the duration of antibiotic therapy
Time frame: 3 month
Plan to share: Undecided
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →